| http://purl.uniprot.org/citations/35028603 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/35028603 | http://www.w3.org/2000/01/rdf-schema#comment | "Dendritic cells (DCs) excel at cross-presenting antigens, but their effectiveness as cancer vaccine is limited. Here, we describe a vaccination approach using mesenchymal stromal cells (MSCs) engineered to express the immunoproteasome complex (MSC-IPr). Such modification instills efficient antigen cross-presentation abilities associated with enhanced major histocompatibility complex class I and CD80 expression, de novo production of interleukin-12, and higher chemokine secretion. This cross-presentation capacity of MSC-IPr is highly dependent on their metabolic activity. Compared with DCs, MSC-IPr hold the ability to cross-present a vastly different epitope repertoire, which translates into potent re-activation of T cell immunity against EL4 and A20 lymphomas and B16 melanoma tumors. Moreover, therapeutic vaccination of mice with pre-established tumors efficiently controls cancer growth, an effect further enhanced when combined with antibodies targeting PD-1, CTLA4, LAG3, or 4-1BB under both autologous and allogeneic settings. Therefore, MSC-IPr constitute a promising subset of non-hematopoietic antigen-presenting cells suitable for designing universal cell-based cancer vaccines."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.xcrm.2021.100455"xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Chen J."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Pelletier J."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Robert F."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Olivier M."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Talbot S."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Trudeau L.E."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Annabi B."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Rafei M."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Balood M."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "El-Hachem N."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Khodayarian F."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Roversi K."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Abusarah J."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Bikorimana J.P."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "El-Kadiry A.E."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Jolicoeur M."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Kamyabiazar S."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Salame N."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/author | "Shammaa R."xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/date | "2021"xsd:gYear |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/name | "Cell Rep Med"xsd:string |
| http://purl.uniprot.org/citations/35028603 | http://purl.uniprot.org/core/pages | "100455"xsd:string |